Q3 2025 Management View David Meeker, Chairman, President & CEO, highlighted "strong growth and continued momentum during the third quarter as we prepare to launch IMCIVREE in acquired hypothalamic ...
Third quarter 2025 net product revenue from global sales of IMCIVREE® (setmelanotide) of $51.3 million -- -- December 20, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback